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ABBREVIATIONS 
Ala  Alanine 
Asp  Aspartic acid 
BTCP  1-[1-(2-Benzo[b]thienyl)cyclohexylpiperidine 
CFT  2β-Carbomethoxy-3β-(4’-fluorophenyl)tropane 
CPM  Counts per minute 
dDAT  Drosophila melanogaster dopamine transporter 
DAT  Dopamine transporter 
DiPEA  N,N-Diisopropylethylamine 
Ea  Activation energy 
FP  Fluoropropyl 
GBR12909 1-(2-[Bis(4-Fluorophenyl)methoxy]ethyl)-4-(3-
phenylpropyl)piperazine 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HPLC  High-performance liquid chromatography 
IC50 The median concentration of an inhibitor that causes 50% 
inhibition of a given system 
ki  Isomerization on-rate constant 
k-i  Isomerization off-rate constant 
kinact  Inactivation rate constant 
Ki  Inhibition constant 
Kisom  Isomerization constant 
KL  Dissociation constant of the initial binding 
LeuT  Leucine transporter 
NBS  N-Bromosuccinimide 
NET  Norepinephrine transporter 
PE2I  N-(3-Iodoprop-(2E)-enyl)-2β-carbomethoxy-3β-(4’-
methylphenyl)nortropane 
PET  Positron emission tomography 
Phe  Phenylalanine 
POPC  1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
RTI  Research Triangle Institute 
SEM  Standard error of the mean 
SERT  Serotonin transporter 
SPECT Single photon emission computed tomography 
SPR  Surface plasmon resonance 
9 
Ser  Serine 
SLC6  Solute carrier 6 gene family 
TEA  Triethylamine 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
Tyr  Tyrosine 
Val  Valine 
WIN35,428 2β-Carbomethoxy-3β-(4’-fluorophenyl)tropane 
WIN  Winthrop 
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INTRODUCTION 
Dopamine transporter (DAT) is a 12-transmembrane protein, belonging to a 
neurotransmitter-sodium symporter family, responsible for the uptake of 
dopamine from postsynaptic cleft and is widely expressed in mammalian brain. 
DAT is target for various therapeutic drugs used for treatment of psychiatric 
diseases and disorders, e.g. depression, anxiety, attention deficit hyperactivity 
and epilepsy. Several psychostimulants, like cocaine or amphetamine, also 
target monoamine transporters, including DAT.1 One of the driving forces for 
DAT study is the search for specific ligands which inhibit the binding of 
cocaine, or its analogues, while maintaining the transport of substrate. 
Langley reported in 1905 that nicotine and curare caused tonic contraction in 
the muscles of frog legs long after nerve section.2,3 The phenomenon was 
further mathematically described by Archibald Hill in 1909, who reported that 
the time-curves of muscle twitching, when muscles were submerged in the 
solution of nicotine, followed an exponential function.4 This was one of the first 
studies of drug action kinetics, although the target protein was not identified. 
Nowadays it is known that the effect was caused by the binding of nicotine to 
nicotinic acetylcholine receptor.5,6 Publication of reports on protein-ligand 
interaction kinetics accelerated in the 1970s with thorough investigation of 
nicotinic acetylcholine receptor agonists and antagonists.7,8 
Strickland, Palmer and Massey proposed a two-step protein-ligand inter-
action model, where the overall dissociation constant is determined by two sub-
sequent equilibria.9 Modulation of these equilibria allows enhancement of the 
apparent drug affinity. However, this option has not been discussed and con-
sidered widely. One of the possible reasons is that the presence of the second 
step in binding process can be identified only by kinetic experiments, and the 
one- and two-step interaction mechanisms cannot be differentiated by standard 
displacement studies. Since that time kinetic approach has been used to cha-
racterize the binding mechanism and rate constants of the slow step of 
numerous ligand-protein systems, including muscarinic acetylcholine 
receptor,10,11 dopamine receptor12 and dopamine transporter13,14. 
In 2006 Copeland and others introduced a simplified metric, drug residence 
time, to characterize the slow drug-target off-rate.15 Although drug residence 
time, defined as the reciprocal of the off-rate kinetic constant, lacks a clear 
physical meaning, it could be easily determined by in vitro assay methods and 
used in drug development.16 Also, it has highlighted the importance of slow 
ligand off-rate, and therefore, ligand-protein interaction kinetics should be 
recognized as a crucial part of a lead compound optimization process in drug 
discovery.17 
Ideally, the kinetic parameters of a ligand-protein interaction should be 
determined experimentally for each compound under investigation. Since 
labeling of every compound of interest is not feasible, an indirect method is 
used, where the influence of an unlabeled ligand on the binding kinetics of a 
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single labeled ligand is studied. Therefore, the same reporter ligand can be used 
for kinetic studies of a series of unlabeled ligands and this has made the kinetic 
approach effective and comparable with the well-known ligand displacement 
method. 
In this study, the kinetic analysis of DAT interaction with ligands was imple-
mented to study the interaction of a series of N-substituted 2β-carbomethoxy-
3β-(4’-methylphenyl)-nortropanes with this protein by using a selective DAT 
ligand [3H]PE2I as the reporter ligand. 
In parallel with kinetic study of ligand-DAT interaction mechanism, stability 
of the membrane-integrated protein and its thermal inactivation kinetics were 
investigated to consider these results in the planning of kinetic experiments. 
This study clearly pointed out that the role of membrane environment of the 
protein cannot be overestimated in explanation of its properties.  
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LITERATURE OVERVIEW 
Dopamine transporter 
Dopamine transporter (DAT) belongs to a family of sodium-neurotransmitter 
symporters, i.e. Na+ is transported in the same direction as substrates, with other 
neurotransmitter and amino acid transporters.18 The solute carrier 6 (SLC6) 
transporter family has been divided into the following subfamilies on the basis 
of similarity: monoamine, amino acid, γ-aminobutyric acid and amino acid/ 
orphan. SLC6 family itself belongs to a solute carrier superfamily consisting of 
approximately 350 transporters. In addition to being targets of numerous 
medications, the monoamine transporters of dopamine, norepinephrine (NET) 
and serotonin (SERT) are targets for some of the most widely used drugs of 
abuse, e.g. cocaine, amphetamine/methamphetamine and methylenedioxymeth-
amphetamine.1 Transgenic models give a simplified overview of the role of 
dopamine transporter. DAT-knockout mouse models have shown a fourfold 
increase in extracellular dopamine concentrations leading to dopamine dys-
regulation, which in turn causes hyperlocomotion, impaired cognition and other 
behavioral impairment.19 On the contrary, DAT overexpression increases 
dopamine uptake by half, decreases the extracellular dopamine concentrations 
and dopamine release by half giving rise to loss of dopamine neurons causing 
fine motor deficits in mice.19 DAT function is associated with several proteins, 
including phosphatases, G protein-coupled receptors, receptor tyrosine kinases, 
cytosolic kinases, membrane trafficking and scaffolding proteins.20,21 Inter-
actions between these proteins and DAT are thought to alter surface expression 
of DAT and regulate DAT functions, e.g. reverse transport.20 
 
 
 
Figure 1. Dopamine transporter (green ribbon) obtained from protein database (4M48).26 
All stabilizing compounds are removed from this structure and phospholipid (POPC) 
shell is introduced. 
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In order to understand the molecular mechanisms of transporter action, its 
detailed structure would be a necessity. The determination of transmembrane 
leucine transporter (LeuT) structure gave information about the possible structure 
of DAT,22 and on the basis of LeuT structure, several DAT-ligand docking 
simulations have been reported.23–25 These studies revealed potential substrate 
and inhibitor binding sites. After publishing Drosophila melanogaster DAT 
crystal structure26 (Figure 1), a more detailed binding modelling of the protein, 
as well as binding sites of known inhibitors and substrates which are important 
for screening of new drug candidates, has been published.27 Recent findings 
verify previous results, obtained from LeuT structure.23,28 These results indi-
cated that the dopamine binding site overlaps with the binding sites of cocaine 
and its analogues. This postulate contradicts a LeuT structure based DAT 
simulation study,25 reporting that the dopamine and cocaine binding sites do not 
overlap, but are in close proximity. In addition, cocaine can always bind to 
DAT, whether dopamine has already been bound or not, although DAT affinity 
for it decreases.25 The binding of non-catecholic DAT substrate-like inhibitors, 
amphetamines, is also explained by their interaction at the central dopamine 
binding site, despite the fact that these ligands omit hydroxyl groups, which are 
important structure fragments of dopamine (Scheme 1).23 
Crystallization studies of ligand-DAT complexes also reveal information 
about the amino acids making up the binding pocket. The amine group of 
tropane derivatives (Scheme 2) forms a salt bridge with Asp46 and the phenyl 
group is attracted by the aromatic interaction with Phe325 in dDAT.28 This indi-
cates the necessity of nitrogen, or any other hydrogen bond acceptor, and phenyl 
group in DAT ligands. Superposition of β-CFT-dDAT, β-CIT-dDAT and 
cocaine-dDAT reveals that these ligands (Scheme 2) overlap almost entirely. 
The benzoate group of cocaine and the halide-substituted phenyl groups of  
β-CIT and β-CFT form van der Waals interactions with Ser422, Phe325, 
Tyr124, Val120 and Ala117 in the binding site.23,28 The bulky tropane bicycle is 
bordered by Ser421, Phe319, Ala48, Asp46, Ala44 and Phe43. The DAT 
binding pocket is quite conserved and surrounded by mostly hydrophobic amino 
acid residues, demonstrating the need of an aliphatic backbone connecting a 
hydrogen bond acceptor group with aromatics. The inhibition of dopamine 
binding is achieved by the combined interactions of free amine, bulky tropane 
ring and aromatic phenyl ring hindering the conformational movements of 
DAT.28 However, it is important to emphasize that all these interactions have 
been revealed as crystal structures of ligand-DAT complexes, where the role of 
the lipid-protein complex dynamics is not considered. 
Mutagenesis studies have highlighted the amino acid residues Asp313 and 
Trp84 to be in or near the DAT binding pocket of cocaine and its analogue,  
β-CFT, since aspartate to asparagine and tryptophan to leucine mutations have 
increased the DAT’s affinity for these ligands compared to wild-type. On the 
other hand, these mutations did not enhance, but decrease the binding affinity of 
piperazine-based inhibitors, e.g. GBR12909 (Scheme 2).29,30 This suggests that 
tryptophan and aspartate are vital for GBR12909 analogues to retain strong 
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interactions with DAT, while Asp313 and Trp84 are somewhat inhibiting the 
interaction of tropane-based inhibitors. 
 
 
DAT ligand types 
Structures of various DAT ligands can be divided roughly into two main 
groups: 
a)  ligands that act either as substrates or partial allosteric modulators, 
b)  inhibitors.21 
 
The former group consists of dopamine and structurally similar molecules 
(Scheme 1), which are potentially transportable ligands. The latter group is made 
up of inhibitors of various classes of compounds (Scheme 2), most potent are 
benzhydryl substituted piperazine derivatives (e.g. GBR12909 and GBR12935) 
and cocaine-like molecules (e.g. β-CPT).21,31 
 
 
Scheme 1. Dopamine and other substrate-like DAT ligands. 
 
A significant amount of literature focuses on piperazine-based compounds to 
find selective DAT inhibitors and it has been the second most probed scaffold 
besides tropane bicycle.32–37 Among them GBR12909, also known as vanoxerine 
(Scheme 2), even entered clinical trials as a medication to treat psychostimulant, 
e.g. cocaine and methamphetamine, drug abuse but failed on its Phase I trials 
due to side-effect liabilities.38,39 Some piperazine derivatives are also high 
affinity sigma receptor ligands, for example rimcazole is both DAT inhibitor 
and sigma-1 receptor antagonist.40 It’s thought that the dual interaction with 
DAT and σ receptors is a potential solution against psychostimulant 
addictions.32,41 Among piperazine-based ligands the DAT affinity is usually not 
a problem, but the selectivity against other monoamine transporters and receptors 
is an issue. 
A separate class of DAT inhibitors are benztropine analogues (Scheme 3a), 
while benztropine itself is used as an anticholinergic agent.42 Benztropine and 
its N-substituted analogues have quite recently reported to be antagonists of 
cocaine and amphetamine self-administration.43 The structure is similar to 
cocaine derivatives in that the tropane bicycle is the same, but benztropine has 
no substituent at the C-2 position and the C-3 substituent is in the endo or  
α-configuration (Scheme 3a). Benztropine and GBR-compounds share the same 
diphenylmethoxy moiety, which contributes to the different binding interactions 
OH
OH
NH NH NH
dopamine )-amphetamine )-methamphetamine
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with DAT.29 Numerous benztropine derivatives have been synthesized and their 
monoamine transporter affinities determined to yield several potent ligands.44 
 
 
Scheme 2. Selection of DAT inhibitors. 
 
Several other scaffolds for lead optimization of selective and potent DAT ligands 
have been proposed, e.g. trishomocubane,45 substituted pyridines,46 bivalent 
phenetylamines,47 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methyl-
phenyl ketone,48 1-[1-(2-benzo[b]thienyl)cyclohexylpiperidine (BTCP)49 and 
methylphenidate50(Scheme 3b-g). 
Polycarboxylic trishomocubane derivatives are σ receptor inhibitors, which 
had off-target affinity for other receptors in mammalian brain and their potential 
application for DAT imaging agent was investigated.45 Wang and others 
focused on the geometrical positions and distances between nitrogen, carbonyl 
and phenyl ring of 3β-phenyltropanes to develop a new class of DAT inhibitors.48 
This approach did not yield ligands of even moderate monoamine transporter 
affinity. Enyedy et al. have more successfully managed the design of aryl-
substituted pyridines as potent DAT ligands using similar technique of gene-
rating a new pharmacophore model from structural features of several classes of 
known DAT inhibitors.46 Several pyridine-based DAT inhibitors with sub-
nanomolar affinities and good selectivity were developed.46 BTCP, an analogue 
of the abused drug phencyclidine, is known to be a dopamine uptake inhibitor 
and derivatives of BTCP have been developed to have moderate potency.49,51 
All of the aforementioned ligands are atypical dopamine transporter inhibitors 
and their derivatives have been thoroughly investigated, nevertheless their use 
has been quite scanty. 
N O
O
R
N O
O
O
O
(−)-Cocaine R=I β-CIT
R=F β-CFT
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O
N
N
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Scheme 3. Benztropine(a), trishomocubane (b), substituted pyridines (c), bivalent 
phenetylamines (d), 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl 
ketone (e), 1-[1-(2-benzo[b]thienyl)cyclohexylpiperidine (f), methylphenidate (g) as DAT 
inhibitor scaffolds. 
 
 
Tropane derivatives as DAT inhibitors 
The extensive search for a potent monoamine transporter inhibitor among 
tropane derivatives, to find drugs for disorders connected with transporter, 
started in the 1970s with the identification of transporters as drug targets and 
intensified in 1990s with the cloning of transporter cDNA.1 Several structural 
features determine the binding potency of cocaine-like ligands to DAT: stereo-
chemistry and substituents at C-2, C-3 and N-positions of tropane core 
(Scheme 2).52,53 Naturally (–)-cocaine, with substituents at C-2 and C-3 
positions in the β-configuration (Scheme 2), has eight possible stereoisomers of 
which only (R)-(2β,3β)-cocaine is a potent psychostimulant.29 Several reports 
confirm the sensitivity of DAT to the stereochemistry of the bicycle.14,52,53 
Therefore, synthesis starting from natural alkaloids allows to retain most of the 
stereocenters. One of the first modifications to yield tropane ligands with higher 
biological activity than cocaine, was the replacement of the benzoyloxy group 
by phenyl ring at the 3-position of cocaine (Scheme 2).54,55 This replacement 
was the basis for the design of more potent DAT inhibitors. Modification of the 
[3.2.1]bicycle by elimination of the ethylene bridge of 3β-phenyl tropanes 
diminished its potency substancially.54 
A significant correlation between potencies and self-administration exists 
among cocaine analogues, and therefore, self-administration can be predicted by 
DAT’s affinity to compounds; this phenomena is absent among other monoamine 
transporters, e.g. NET and SERT.56 The effect of substituents of tropane 
N
O N
OH
N
R
a b c d
NH NHOH
OH
OH
OH
NH NH
n
6
e
N
OH
O
f
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g
N
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derivatives to DAT potency and selectivity and some applications are discussed 
in the following paragraphs. 
Introduction of reactive groups to potent DAT inhibitors allows to attach 
ligands to the protein binding pocket covalently. Azido-, isothiocyanate-and 
bromoacetate-based benztropine derivatives were developed as irreversible 
DAT inhibitors as potentially useful molecular probes.57–59 An irreversible DAT 
ligand RTI-76 (3β-(p-chlorophenyl)tropan-2β-carboxylic acid p-isothiocyanato-
phenylethyl ester) has been used to study the possibility of oligomeric 
assemblies among transporter proteins and rodent behavioral effects of blocking 
DAT to determine dopamine agonists and antagonists.59,60 
The sensitivity of DAT to the C-2 position of tropane bicycle (Scheme 2) has 
been probed in several reports.61–65 A set of fluoroalkyl esters and amides at the 
C-2 position of 3β-halophenyltropanes were tested against monoamine trans-
porters to reveal that esters showed higher affinity than amides at both DAT and 
SERT. Even the tosylate esters had nanomolar affinities suggesting that SERT 
and DAT can tolerate bulky substituents at the C-2 position in β-configu-
ration.63 In order to increase the metabolic stability, the ester group at C-2 
position of tropane ring has been replaced with substituted oxadiazol61 and other 
heterocyclic66 moieties and these modifications usually retained biological 
activity. This replacement also yielded ligands with slower onset of action and 
lower abuse liability than cocaine, and therefore, has been proposed as a 
substitute medication for treating cocaine abuse.61 Even a series of dimeric 
tropane analogues, connected at position C-2 with different linkers, have been 
synthesized and their biological activity determined.67 This analysis revealed 
that with an appropriate linker good DAT affinity could be achieved, but the 
binding to other monoamine transporters was also significant. Dimerization of 
high affinity ligand did not guarantee excellent binding of the dimeric 
compound.67 
The DAT sensitivity to the C-3 position of tropane bicycle (Scheme 3) has 
been probed with bulky substituents at the 4’-position, revealing a remote 
binding cavity approximately two methylene groups from the 4’-position, on the 
DAT.68 This cavity allows insertion of another aryl group to 4’-position when 
appropriate, e.g. (E)-olefinic, acetylenic or methyl acetylenic, linker is used.68 
Increase in potency, by addition of an extra aryl group, was not achieved, but 
the possibility to attach functional groups in order to improve any other 
property of the compound remains. The steric sensitivity of DAT to substituted 
4’-phenyltropanes was studied also by Blough and others to find that 
substituents larger than ethyl group resulted in lower affinity for DAT and 
lower selectivity when compared to SERT.69 From this, it can be concluded that 
phenyl, 4’-methylphenyl and 4’-halophenyl groups at 3β-position usually 
increase or retain DAT affinity, however, if large aromatic substituent is needed 
at 4’-position, a linker of at least few carbons would be necessary. 
Combination of removal of N-methyl group with the addition of 4’-ethyl and 
3’-iodo substituents led to a high affinity and selectivity for the SERT.70 
Replacement of N-methyl group with a functional group containing N-N bond 
18 
led to a significantly lower potencies compared to cocaine. This could be 
explained by the fact that decrease in electron density at the bridge nitrogen is 
responsible for the decrease in activity. This is not always the case since 
exchange of nitroso group with more electron withdrawing nitro group 
increases the potency more than tenfold. A discrepancy between dopamine 
uptake inhibition and binding affinities showed that some cocaine analogs were 
more active in the displacement experiments than in dopamine uptake inhibition, 
suggesting a possibility that these compounds are functional antagonists of 
cocaine.71 
It has been suggested that from a steric point of view nortropane derivatives 
accommodate only small changes at the nitrogen position or on the aromatic 
ring at C-3.53 Nevertheless, N-position of tropane bicycle has been probed by 
several reports.71–73 The monoamine transporter affinities of N-substituted 
derivatives of β-CIT were analyzed and it was revealed that the basicity of 
tropane nitrogen was the only factor to determine DAT affinity if bulky and 
polar groups were introduced to the tropane nitrogen. It was concluded that 
even sterically large substituents are tolerated if the spacer is long enough.72 
Quaternization of cocaine and zwitterionic 2β-carboxylic acid cocaine 
derivative resulted in a loss of DAT bioactivity in a few orders of magnitude.74 
Transition metal (Cr and Ru) complexes of 2β-carbomethoxy-3β-phenyl-
tropane were synthesized in order to search potent ligands with spectrochemical 
(Cr(CO)3) or radioactive (97Ru) labels to probe biological systems.75 The 
resultant Cr and Ru tropane complexes yielded low to moderate affinity ligands, 
which were rarely used afterwards. 
The necessity of tropane nitrogen was tested by replacing it with oxygen or 
methylene bridge. This allowed designing of new compounds based on 
bicyclo[3.2.1]octane system, questioning the role of ionic bond of tropane 
nitrogen with hydrogen bond donor of the transporter.76,77 Indeed, more than a 
few 8-oxabicyclo[3.2.1]octane and carbocyclic [3.2.1]octane derivatives showed 
at least as good affinity, and selectivity over SERT, as its nitrogen coun-
terparts.76,77 In addition, the configuration of C-2 and C-3 had also effect on the 
selectivity of DAT over SERT in these series and the absolute requirement of  
β-configuration of both carbons was contradicted, since many 2α and 3α non-
nitrogen ligands were quite potent.76,77 Nevertheless, β-configuration of carbons 
of tropane-based ligands at positions 2 and 3 in most cases yield more active 
DAT ligands than their α-analogues. 
 
 
Reporter ligands 
Numerous radiolabeled ligands have been used to study DAT in vitro. 
[3H]Cocaine,78 [3H]β-CFT,79,80 [3H]β-CPT,81 [3H]Mazindol,71 [3H]GBR12935,73 
[125I]β-CIT82 and [3H]PE2I83 to name a few (Schemes 2–4). In addition, 
[3H]dopamine has been used for uptake studies (Scheme 1).84 Several tropane 
based PET and SPECT ligands have been developed to localize DAT in 
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mammalian brain including [11C]PE2I,85 [18F]FE-PE2I,86, [11C] LBT-999,87 
[123I]FP-CIT,88 [18]FP-CIT,89 [123I]-altropane89 and [99mTc]TRODAT89 (Scheme 4). 
Rhodamine (RTI-233) and 7-nitrobenzo-2-oxa-1,3-diazole labeled fluorescent 
monoamine transporter ligands have been developed, but were moderately 
affine (Scheme 5).90,91 Fluoroprobes RTI-233, MFZ 9-18 and JHC 1-64 still 
have been used only very little to characterize amine transporters92–94 when 
compared to reports using radioactivity labeled cocaine analogs. This could be 
explained by the relatively poor selectivity of these ligands for neurotransmitter 
transporters and by their moderate affinity. 
 
 
Scheme 4. A selection of tropane-based ligands used for the localization of DAT in vivo. 
 
Reporter ligands, used in in vitro displacement studies or in kinetic experiments, 
have to meet several criteria. These ligands must: 
1)  be specific for the target protein, 
2)  have high binding effectiveness, 
3)  form slowly dissociating complex, if slow separation methods are used to 
determine the bound ligand (e.g. filtration, centrifugation), 
4)  share the same binding sites with ligands under investigation, 
5)  carry sensitive labeling for determination of low concentrations, 
6)  be stable in the assay mixture during the analysis. 
 
 
Scheme 5. Some tropane derivatives tagged with fluorescent labels. 
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Simulations of ligand binding kinetics 
Ligand-receptor binding kinetics have been theoretically studied and kinetic 
curves have been simulated in a number of reports. 95–98 This theoretical approach 
would be unavoidable if experimental data reveal complex or uncommon binding 
kinetics. Here are some examples where simulations support experiments. The 
kinetics of chorionic gonadotropin binding to gonadotropin receptors were 
studied and binding time-curves were simulated since the kinetics appeared to 
be multiexponential.95 This phenomenon was explained by the degradation of 
the binding hormone and receptor. A mathematical model, describing the 
simultaneous binding and degradation, was developed and simulated curves 
were computed. This approach allowed to estimate more correct rate constants 
and the extent of degradation.95 Motulsky and Mahan derived a mathematical 
model, and solved it analytically, to simulate the kinetics of simultaneous 
binding of a ligand and its competitive inhibitor to a receptor. The effect of a 
slowly dissociating inhibitor, the length of reasonable incubation times and the 
determination of rate -and equilibrium constants from kinetic curves were 
discussed.96 The effect of aggregation on the binding kinetics was analyzed in 
the case of insulin binding to insulin receptor.97 Complex models, considering 
receptor aggregation and cooperativity, were constructed and the resulting 
differential equations were solved numerically to obtain computer simulations 
explaining kinetic data observed experimentally.97 A situation, where a drug 
molecule can bind to a target protein in different orientations, was theoretically 
analyzed by Wittmann and Strasser.98 The binding time-curves of labeled ligand 
competing with an unlabeled ligand capable of binding in two different 
orientations were simulated by solving a derived differential equation system 
numerically. Resulting kinetic curves of one- and two-orientation models were 
compared with experimental data to distinguish binding mode. Several ligand-
protein systems, where one ligand exhibits a bivalent binding mode, have been 
reported.99,100 The aforementioned cases use simulations of ligand-protein inter-
actions to interpret uncommon experimental data in order to gain a more detailed 
insight about ligand or protein behavior. In all these cases, simulation of ligand-
protein interactions was made to interpret uncommon experimental data and 
gain insight into ligand-protein interaction mechanism. 
 
 
Kinetics of tropane derivatives interaction with DAT  
Although, the inhibition constants of tropane derivatives have been determined 
extensively over the decades, kinetic characterization has not been a priority. 
The binding of [3H]CFT (Scheme 2) to cocaine receptor (nowadays DAT) has 
been studied in 1989 and biexponential time course was found in both 
association and dissociation steps.79 This was explained by two-component 
binding model with 4.7 and 66 nM dissociation constants, designated as high 
and low-affinity components, while the former component comprised about 
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90% of specific binding.79 It was suggested that the low affinity component 
could be binding to other membrane proteins in sample tissue, e.g. other 
monoamine transporters. The low affinity binding site was later shown to be an 
artifact generated by freezing of caudate tissue.101 The half-life of dissociation 
of [3H]CFT was up to 100 times longer than reported for [3H]cocaine, and also 
the non-specific binding of [3H]CFT was almost two times less than that 
observed for [3H]cocaine.79 Due to slower dissociation rate, higher affinity and 
selectivity, compared to [3H]cocaine, [3H]CFT was considered, and extensively 
used today, as a radioligand probe for DAT. 
Hasenhuetl et al. have used electrophysiological approach, i.e. whole-cell 
patch clamp system, to determine kinetic parameters of cocaine, methyl-
phenidate and desipramine binding to DAT and SERT.102 The observed rate of 
cocaine binding to hDAT was observed at multiple concentrations to yield kobs 
versus concentrations graphs. Cocaine showed a linear dependence of the 
apparent rate constant upon ligand concentration, indicating a one-step binding 
mechanism.102,103 The off-rate constant of cocaine-DAT complex was 0.35 s–1, 
which is approximately two orders of magnitude faster than the off-rates of 
slowly dissociating ligands.13,102 
The kinetics of several ligands, including GBR12909 (Scheme 2) and PE2I, 
to DAT have been studied before by Stepanov and Järv.13,104 It has been shown 
that after initial binding of GBR12909 and PE2I to DAT an additional slow step 
of conformational isomerization of the complex occurred (Scheme 6). In 
addition, both ligands had very similar equilibrium and isomerization rate con-
stants, and the contribution of the additional slow step increased the apparent 
affinities of both ligands approximately tenfold. This isomerization phenomena 
was not found in the case of dopamine and cocaine binding.103 
 
Scheme 6. Two-step binding mechanism of PE2I and GBR12909 to DAT. 
 
N-(3-Iodoprop-(2E)-enyl)-2β-carbomethoxy-3β-(4’-methylphenyl)nortropane 
(PE2I) is a selective and potent ligand developed as a dopamine transporter 
inhibitor (Scheme 4).73 PE2I is a DAT inhibitor with approximately 100 times 
greater potency than cocaine.83 Therefore [11C]-labeled PE2I has been one of the 
most used ligands to localize DAT in positron-emission tomography (PET) 
studies.85,105 Since PE2I fulfills all prerequisites of a reporter ligand, it is used in 
this study to characterize other tropane-based ligands. 
The inhibition constants acquired from displacement studies or dissociation 
constant derived from direct binding experiments reflect the overall dissociation 
constant of ligand-protein complex, yet these standardized experiments do not 
give information about the possible kinetic mechanism of ligand binding. 
L L-DAT (L-DAT)+DAT L= PE2I
 GBR12909
rpid slow
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The overall inhibition constant (Ki or Kd) is related to the subsequent equi-
librium constants (KL and Kisom) (describing binding Scheme 6) by the following 
equation: 
 
 ܭ௜ = ௄ಽ௄೔ೞ೚೘௄೔ೞ೚೘ାଵ (1) 
 
 
Methods for the analysis of membrane protein-ligand 
interaction in vitro 
Although, there are numerous methods to study the binding interactions between 
membrane proteins and ligands, only handful have been used to study ligand 
binding kinetics. Methods like isothermal titration calorimetry,106 circular 
dichroism spectroscopy,107 atomic force microscopy108 and NMR109 have been 
used to investigate some aspects of membrane protein-ligand binding, but have 
found little use when kinetic studies are in mind, due to several shortcomings 
inherent to those methods. 
 
 
Radioactive ligand binding 
Radioligand binding assay is the most versatile method so far to quantify 
equilibrium or kinetic parameters of membrane protein-ligand interactions. 
Although, being a relatively old method, it is still in use to validate any novel 
methods. The first kinetic evaluations started with the progress on radiolabeling 
techniques. In 1957 Wilzbach proposed a tritium-labeling method, where the 
compound of interest is exposed to tritium gas and the exchange of hydrogen to 
tritium occurs.110 This method allowed preparation of [3H]atropine to kinetically 
characterize the direct binding kinetics of atropine to acetylcholine receptor.111  
The direct measurement of a radioligand kinetics is always more desirable, but 
in most cases a reasonable result can be obtained from indirect measurements. 
Several procedures exist to determine whether ligand forms a slowly dissociating 
stadium and to determine rate constants. “Infinite dilution” or isotopic dilution 
technique was proposed to measure the off-rate of radioligand from its complex 
with the target protein by a substantial dilution, this can be accompanied by the 
presence of an unlabeled compound.112,113 The amount of bound radioligand is 
then determined at different time points after dilution. The dissociation of 
radioligand can also be initiated by the addition of concentrated unlabeled 
ligand with minimal dilution.114 In many cases these techniques reveal different 
results and are often explained with radioligand rebinding after dilution.114 Other 
option is to measure the apparent rate constants of radioligand association with 
increasing concentrations of unlabeled ligand.14,115,116 This yields an observed 
rate versus concentration plots which could be solved to give rate constants of 
the slow step of ligand under investigation. There’s also a method by Motulsky 
and Mahan, where the rate constants of an inhibitor are determined by measuring 
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the effect of a single concentration of unlabeled inhibitor on the observed rate of 
the radioligand binding.96,117 It should be noted that this procedure is adequate 
only in the simplest of competitive inhibition cases. 
 
 
Surface plasmon resonance 
A method where the receptor, or the ligand, is immobilized to a sensor surface 
under detergent-solubilized or lipid-reconstituted conditions and the minute 
changes in refractive index at the surface are measured.118 For adequate results it 
is crucial that the protein retains its tertiary structure and activity in the substitute 
environment. The advantages of this method are small amount of material needed 
for a measurement, capability to detect fast complexes and being label-free.118 
On the other hand, the drawbacks include low-throughput, mass transport 
limitation, potential challenges in finding a strategy to attach the protein to a 
surface, while retaining the protein native function in an artificial lipid medium 
and sensitivity of detecting the interactions of small molecules is more difficult 
than of larger ones.118,119 Nevertheless, SPR has been used to characterize kinetics 
of several membrane protein-ligand systems, including DAT120 and D3 dopamine 
receptor121. Based on SPR, handful of related methods have been developed, 
e.g. plasmonic-based electrochemical impedance microscopy (P-EIM)122 and 
SPR microscopy123. 
 
 
Fluorescence-based methods 
Several fluorescence based methods have been developed to study membrane 
protein-ligand interactions. Fluorescent labeled ligands can be used similarly as 
radioligands in determining equilibrium or kinetic constants of a ligand-protein 
system, where bound and free ligand are separated as in radioligand assays, e.g. 
filtration, chromatography, and quantified by fluorescence detector.124 The only 
advantage of this method over radioligand binding would be the absence of 
radioactive waste from experiments. The sensitivity of fluorescence detection is 
typically lower than that of radioactivity, and issues with potential auto-
fluorescence and change in ligand fluorescence emission due to environment 
are some drawbacks of this method.124 A more advanced methods, e.g. based on 
ligand-receptor Förster resonance energy transfer124 or fluorescence anisotropy,125 
has been used to study rapid binding kinetics. Försted resonance energy transfer 
based method needs covalent attachment of a fluorophore to both ligand and 
receptor and is based on the strong distance dependence of energy transfer 
between chromophores or fluorophores attached to the ligand and to the 
receptor.124 It’s important to emphasize that there is a possibility that the receptor 
function can be altered due to modification of the membrane protein structure and 
furthermore, if the fluorophore of a ligand is of comparable size with the ligand 
core structure, it would be difficult to study the effects of substituents of ligands 
since the largest effect would be caused by the fluorophore. 
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AIMS OF THE STUDY 
The general aim of this dissertation was to investigate the kinetic mechanism of 
interaction of cocaine analogs with DAT and determine how this mechanism 
changes with ligand structure. This main goal was divided to the following 
objectives. 
• Synthesis of a series of N-substituted nortropane derivatives for bioactivity 
measurements. 
• Quantification of equilibrium and binding characteristics of interaction of 
DAT with the synthesized compounds. 
• Comparison of shifts in inhibition and kinetic constants with changes in 
molecular structure to give insight about the interactions of DAT with other 
ligands within this bicyclic core structure. 
• Derivation of a mathematical model to simulate binding time-curves of two 
simultaneously interacting ligands with a protein to specify differentiation 
between distinct mechanisms. 
• Analysis of thermodynamic aspects of DAT thermal inactivation and esti-
mation of the role of biomembrane in the stability and dynamic properties of 
transmembrane proteins. 
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EXPERIMENTAL 
General methods 
The buffer components were purchased from Lach-ner or Sigma-Aldrich. What-
man GF/B filters were used for the filtration assays. Fisher ScintiSafe 3 was 
used as a scintillation cocktail for counting of the samples. Radioactivity of the 
samples was measured with either Wallac 1219 Rackbeta or Wallac Guardian 
1414 liquid scintillation counters. The binding data were analyzed using 
GraphPad Prism 4 software. Inhibition constants were calculated from IC50 values 
using Cheng-Prusoff equation126, using 3 nM and 4.8 nM as the concentration of 
radioligand and the dissociation constant. N-(3-Iodoprop-(2E)-enyl)-2β-
carbomethoxy-3β-(4’-methylphenyl)nortropane (PE2I) and its precursor were 
obtained from AS PharmaSynth and radiolabeled with [3H]MeI as described 
before115 yielding [3H]PE2I with specific radioactivity of 69.4 Ci/mmol. The 
molar refractivities of compounds were calculated with ACD ChemSketch 
software. The purities of compounds were determined by HPLC (Agilent 1260–
1290) analysis using a diode-array detector and Phenomenex Gemini-NX C18 
column (5 μm, 4.6 mm × 250 mm), at wavelengths 220 and 254 nm. The purity 
was at least 95% at both wavelengths, except for compound 4j which had purity 
slightly below 95% at 254 nm. Nevertheless, most of the compounds had 
purities above 99%. If conventional purification methods did not yield 
compounds with sufficient purity, additional purification was performed by 
preparative HPLC (Schimadzu) on a Phenomenex Luna C18 preparative column 
(5 μm, 15 mm × 250 mm) or flash chromatography (Biotage Isolera One) with a 
reversed-phase KP-C18-HS cartridge. Nuclear magnetic resonance spectra were 
recorded on a Bruker Avance III or Avance II spectrometer (700 or 200 MHz 
for 1H and 176 or 50 MHz for 13C), using tetramethylsilane (TMS) as internal 
standard. HRMS spectra were obtained using a Varian 910-FT-ICR mass 
spectrometer. Glassware used in air- and moisture-sensitive reactions was flame-
dried or dried in an oven and then cooled under inert gas flow. Anhydrous 
solvents were distilled from CaH2 or LiAlH4 under an inert gas atmosphere. 
 
 
Synthesis 
Although, several synthesis strategies for a series of tropane derivatives 
exist,127–129 starting from cocaine is by far the most common route. This path was 
firstly described by Clarke et al. and further investigated by many others.54,55 
The benefits of this approach would be the fixed configuration of natural 
alkaloid and extensive literature describing it. In short, the starting material 
(1, Scheme 7) was hydrolyzed and the resulting ecgonine was dehydrated with 
POCl3. Subsequent anhydroecgonine was arylated with 4-methylphenylmag-
nesium bromide at temperatures below –40 °C and quenched at –78 °C by TFA 
yielding 2β-methoxy-3β-(4’-methylphenyl)tropane (2).130 N-demethylation was 
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achieved by 2,2,2-trichloroethylchloroformate followed by Zn/AcOH. N-Alky-
lation of secondary amines with alkyl bromides with DiPEA as base in aceto-
nitrile gave compounds 4a–4j.131 Alkylation of nortropane with tributyl-
stannylprop-(2E)-ene chloride in ethanol and halogenation with NBS afforded 
compound 6. 
 
 
Scheme 7. General synthesis scheme of a series of N-substituted 2β-carbomethoxy-3β-
(4’-methylphenyl)nortropanes. (i) HCl, reflux, 24 h; (ii) (a) POCl3, reflux, 4–5 h, 
(b) MeOH, –45 °C 15 min, rt. 12 h; (iii) (a) p-tolylmagnesiumbromide, Et2O, CH2Cl2, 
< –40 °C, 4 h, (b) TFA, –77 °C; (iv) Cl3CCH2OCOCl, reflux, 2 h, (b) Zn/AcOH, rt., 
overnight; (v) Bu3SnCH=CHCH2Cl, EtOH, TEA, KI, reflux, 2 h; (vi) I2, CHCl3, 0–2 °C, 
4 h; (vii) RBr, DiPEA, MeCN, rt…reflux, 1…165 h; (viii) NBS, THF, rt., 1.5 h. 
 
 
DAT 
Membrane fragments of striata from adult C57BL/6 mice (mDAT) were used in 
DAT assay experiments. The striata were rapidly dissected, frozen and stored at 
–80 °C. The tissue was suspended in an ice-cold buffer (120 mM NaCl, 30 mM 
HEPES, 5 mM KCl, pH 7.4), sonicated with an ultrasound homogenizer 
(Bandelin SONOPULS) and centrifuged at 30,000 g at 0 °C for 15 min. The 
supernatant was discarded and the remaining pellet was resuspended in buffer 
and the process was repeated three more times to yield a membrane suspension 
that was divided into aliquots and stored at –80 °C until needed. The final 
membrane concentration was approximately 4 mg of wet tissue/ml. 
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Radioligand displacements 
The membrane suspension of mDAT striatal fragments was preincubated with 
various concentrations of unlabeled ligand at 25 °C for 10 minutes before 
[3H]PE2I, final concentration 3 nM, was added. After1 h of incubation, reaction 
was stopped by cold buffer and filtration. Filters were air-dried before trans-
ferring to scintillation vials. After addition of scintillation cocktail and shaking 
for approximately 12 h, the radioactivity was measured using a Wallac 
Guardian 1414 or Wallac Rackbeta 1219 liquid scintillation counter. 
 
 
Kinetic experiments 
Solution of a fixed concentration of [3H]PE2I was added to a membrane 
suspension of mDAT to start the reaction at 25 °C. Aliquots were taken at 
different time points and the reaction was stopped with ice-cold buffer and 
filtration through GF/B filters. The kinetic curve was obtained after transferring 
filters to vials, addition of scintillation cocktail and measuring the radioactivity 
using liquid scintillation counter. CPM values were obtained using a Wallac 
Guardian 1414 or Wallac Rackbeta 1219 liquid scintillation counter. A more 
detailed procedure is reported in paper14. 
The effect of an unlabeled ligand to the reaction rate of [3H]PE2I was 
conducted as follows. A solution of [3H]PE2I (final concentration 3 nM) and 
various concentrations of unlabeled ligands were added to a membrane 
suspension of mDAT at 25 °C. The reaction was stopped and the kinetic curve 
was obtained as described above.14 
 
 
Isomerization step 
The binding mechanism of unlabeled ligand was analyzed by monitoring the 
influence of unlabeled ligand concentration on the observed rate constants (kobs) 
of radioligand ([3H]PE2I) binding with DAT. If the apparent rate of radioligand 
reaction increases, the pool of binding site decreases due to the isomerized 
complexes of both ligands, and therefore, the remaining protein is consumed 
faster. The apparent rate versus concentration of unlabeled ligand plot follows a 
hyperbolic dependence and the equilibrium binding constant (KL) and rate 
constants (ki, k-i) can be obtained104,132,133: 
 
 ݇௢௕௦ = 	 ௞೔
∗[௅∗]
௄ಽ∗∗ ା	[௅∗]
+ 	 ௞೔[௅]௄ಽା[௅] +	
௞ష೔∗ ା௞ష೔
ଶ 	 (2) 
 
Similarly, if the observed rate constant, describing radioligand interaction with 
the binding sites in the presence of various concentrations of the unlabeled 
ligand, decreases, the equilibrium binding constant (KL) of the unlabeled ligand 
could be calculated by the following equation132,133: 
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 ݇௢௕௦ = 	 ௞೔	
∗[௅∗]
(ଵା	[௅] ௄ಽ⁄ )௄ಽ∗∗ 	ା	[௅∗]	
+ ݇ି௜∗  (3) 
 
 
Simulation of protein-ligand interaction 
A mathematical model describing simultaneous binding of two ligands (A and 
B) to protein (R) (Scheme 8) was constructed using principles of mass con-
servation and concepts of physical chemistry. Solving the subsequent ordinary 
differential equation system numerically allows simulating binding time-curves 
of the reporter ligand A. 
 
 
Scheme 8. General receptor (R), ligand (A) and ligand (B) interaction scheme. 
 
Interactions, described in scheme 8, were presented by the following system of 
ordinary differential equations: 
 
ୢ[ୖ୅]
ୢ୲ = ݇଴ଵ([A]୘୭୲ − ([RA] + [(RA)] + [RAB] + [(RAB)]))([R]୘୭୲ −([RA] + [RB] + [(RA)] + [(RB)] + [RAB] + [(RAB)])) +
݇ଶଵ[(RA)] + ݇ହଵ[RAB] − (݇ଵ଴ + ݇ଵଶ)[RA] − ݇ଵହ[RA]([B]୘୭୲ −([RB] + [(RB)] + [RAB] + [(RAB)]));  
 
ୢ[ୖ୆]
ୢ୲ = ݇଴ଷ൫[B]୘୭୲ − ([RB] + [(RB)] + [RAB] + [(RAB)])൫[R]୘୭୲ −
([RA] + [RB] + [(RA)] + [(RB)] + [RAB] + [(RAB)])൯ +
݇ସଷ[(RB)] + ݇ହଷ[RAB] − (݇ଷ଴ + ݇ଷସ൯[RB] − ݇ଷହ[RB]([A]୘୭୲ −
([RA] + [(RA)] + [RAB] + [(RAB)])); 
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where coefficients kij describe the corresponding rate constants, terms in square 
brackets are the molar concentrations of complexes depicted in Scheme 8. 
Formation of the complex (RA) was analyzed with a sum of two exponents to 
yield the specific binding (a) and reaction rate coefficients (b): 
 
 [(RA)] = −ܽ ∙ expି௕௧ − ܿ ∙ expିௗ௧ (4) 
 
MATLAB version 9.1.0 with Curve-Fitting Toolbox (2016b, Mathworks, USA) 
was used for the simulations. The ordinary differential equation system was 
solved numerically with the MATLAB ode23s function designed to solve stiff 
differential equations. The simulated [(RA)] formation time curves were fitted 
with the MATLAB fit function with option exp2 (Equation 4).134 
 
ୢ[(ୖ୅)]
ୢ୲ = ݇ଵଶ[RA] − ݇ଶଵ[(RA)]; 
 
ୢ[(ୖ୆)]
ୢ୲ = ݇ଷସ[RB] − ݇ସଷ[(RB)]; 
 
ୢ[ୖ୅୆]
ୢ୲ = ݇ଵହ[RA]([B]୘୭୲ − ([RB] + [(RB)] + [RAB] + [(RAB)]) +
݇ଷହ[RB]([A]୘୭୲ − ([RA] + [(RA)] + [RAB] + [(RAB)])) +
݇଺ହ[(RAB)] − (݇ହଵ + ݇ହଷ + ݇ହ଺)[RAB]; 
 
ୢ[(ୖ୅୆)]
ୢ୲ = ݇ହ଺[RAB] − ݇଺ହ[(RAB)],  
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RESULTS AND DISCUSSION 
Kinetics of DAT thermal inactivation 
The knowledge of speed of spontaneous loss of binding sites is vital when 
designing experiments, where longer incubation times of reaction mixture with 
protein samples are needed. Therefore, thermal inactivation kinetics of DAT 
was studied by quantifying the specific binding of a selective DAT radioligand 
[3H]PE2I over time. The time-course of spontaneous loss of DAT binding sites 
was monitored at different temperatures (Figure 2). This inactivation kinetics 
was not changed in the presence of protease inhibitor cocktail (Roche), 
confirming the fact that the observed process was not caused by proteolytic 
action of enzymes. 
The decay of specific binding was monitored at 0, 12, 25 and 37 °C, and it 
was found that the thermal inactivation was described by exponential function: 
 
 ܤ௧ = ܤ௡௦ + ܤஶ݁ݔ݌(−݇௜௡௔௖௧ݐ) (5) 
 
where ܤ௧ is the observed radioligand binding at time moment t, ܤ௡௦ is the non-
specific radioligand binding,	ܤஶ is the maximum specific binding and kinact is 
the DAT inactivation rate constant. Specific binding at time t was calculated as 
Bsp = Bt – Bns. The inactivation rate constants were calculated by using Eq. 5. 
Summary of the results obtained for rodent DAT are presented in Table 1. 
 
 
Figure 2. Arrhenius plots of thermal inactivation of mDAT (a), rDAT (b) from striatal 
membranes and rDAT (c) from PC-6.3 cell membranes. 
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DAT is not very stable in the form of a membrane suspension at 25 °C and 
above. Therefore, the incubation times used for binding studies and kinetic 
experiments should be chosen so that the loss of active sites through 
inactivation process remains negligible. In this thesis, the kinetic experiments 
were performed at 25 °C with timeframe in the order of ten minutes, whereas 
the half-life of loss of mDAT binding sites at the same temperature is approxi-
mately 330 min. This indicates that the contribution of thermal inactivation 
during kinetic experiments is negligible. 
 
Table 1 Rate constants of thermal inactivation of dopamine transporters from brain 
striatal and cell membranes. Data from paper I. 
Temperature kinact · 103, min–1 
mDAT rDAT rDAT (PC-6.3 cell-line) 
0˚C 0.26 ± 0.05 0.37 ± 0.05 0.33 ± 0.08 
12˚C 0.76 ± 0.05 0.97± 0.09 0.80 ± 0.1 
25˚C 2.1 ± 0.5 2.1 ± 0.1 1.2 ± 0.1 
37˚C 3.0 ± 0.2 3.7 ± 0.3 3.9 ± 0.6 
 
 
Comparison of thermal inactivation of DAT with stability  
of other proteins 
In order to position the DAT stability among the stability of other proteins, the 
activation energies of thermal inactivation of other membrane and soluble 
proteins were compiled from the literature.135–148 It was found that the activation 
energy of protein denaturation depends on the size of the protein molecule, and 
this dependence can be illustrated in the activation energy (Ea) versus molecular 
weight (MW) plot (Figure 3). This plot includes data for single subunit soluble 
and transmembrane proteins. It can be seen that soluble and membrane proteins 
behave very differently, and data for DAT inactivation agree with the latter 
group of proteins. 
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Figure 3. Comparison of activation energy of thermal inactivation of soluble (□) and 
membrane (●) proteins. Soluble proteins: G-actin,135 stem bromelain,136 carboxypeptidase 
A,137 thermolysin,138 RTX-8,139 Cry3 δ-endotoxin,140 lipase 1,141 acetylcholinesterase142 
and peroxidase143; transmembrane proteins: hDVAC-2,144 muscarinic receptor M1,145 
dopamine D1 receptor,146 mDAT, rDAT from rat striatum, rDAT from PC-6.3 cell line, 
Ca2+-ATPase from myosin and actomyosin,147 human Ca2+-ATPase148. 
 
Simulation of protein-ligand interaction kinetics 
To establish how unlabeled ligands affect the kinetics of interaction of a labeled 
compound with a protein, a series of simulations were undertaken. This was 
accomplished by deriving a mathematical model describing the interactions of 
two ligands with a receptor (Scheme 8), solving the derived ordinary differential 
equation system numerically, and by calculating the specific binding time curves 
of reporter ligand A and receptor R complex formation. For similarity with 
experimental radioligand binding assay, formation of the isomerized complex 
(RA) was simulated, as this complex is determined by using slow methods (e.g. 
filtration) to separate the bound from unbound radioligand. This mathematical 
model allows simulation of kinetic behavior of interaction of two competing 
ligands binding in different mechanisms, therefore, providing an oppurtunity to 
distinguish slowly dissociating complex and possibly inhibition mode. For this 
analysis, the dependencies of ligand concentrations on the specific binding and 
the observed rate constant of the reporter ligand interaction with the binding site 
should be determined. By contrasting these plots, the two reaction schemes can 
be differentiated. 
Firstly, if ligand B forms only rapidly dissociating complex with receptor R 
(Scheme 9), the observed rate and specific binding of reporter ligand A binding 
to R decreases with increasing concentrations of B (Figures 4a and 5a). 
 Decrease in specific binding of A with increasing B concentrations is expected 
when ligands competitively inhibit the binding of each other and this effect can 
always be overcome by addition of A, as seen in Figure 4a. Similarly, the 
observed reaction rate decreases with increasing B concentration and this can 
also be overcome with sufficiently high A concentration (Figure 5a). 
 
 
 
Secondly, if both ligands A and B initiate isomerization step (Scheme 10), a 
decrease of specific binding with increasing concentration of competitive ligand 
B is expected (Figure 4b), similarly as in Figure 4a. However, the observed rate of 
reporter ligand A binding increases with increasing presence of ligand B (Figure 
5b). This completely different trend is a clear indicator of reaction mechanism, 
illustrated in Scheme 10 and it’s caused by faster depletion of the receptor to a 
stable unlabeled ligand-receptor isomerized complex with an unlabeled ligand. 
      
 
Figure 4. The effects of concentrations of competitive ligands A and B to the relative 
specific binding of ligand A: ligand B forms only rapid complexes with R (a); ligand B 
is capable of forming an additional slow step (b). 
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Scheme 9. Competitive binding of reporter ligand A and ligand B. B forms only rapidly 
dissociating complex RB. 
Scheme 10. Competitive binding of reporter ligand A and ligand B. After initial binding B 
forms an isomerized complex (RB). 
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Figure 5. The effects of concentrations of competitive ligands A and B to the relative 
observed rate of binding ligand A binding to receptor R: ligand B forms only rapid 
complexes with R (a); ligand B is capable of forming an additional slow step (b). 
 
 
Characterization of ligands 
The synthesized ligands were characterized by measuring the DAT interaction 
constants, i.e. inhibition constant (Ki), initial equilibrium dissociation constant 
(KL), on- and off-rate constants (ki, k-i) of the isomerization step. These constants 
were determined relative to the radioligand [3H]PE2I. The inhibition constant 
values were calculated from IC50 values, derived from standard displacement 
experiments. All ligands, discussed here, completely inhibited the radioligand 
binding to DAT, revealing a typical single sigmoid and, therefore, indicating to 
a single binding site. The plateaus of kinetic curves also represented data points 
in inhibition curve and coincided with displacement studies, confirming that the 
kinetic curve indeed reached a plateau. 
 
 
Effect of ligand structure to DAT affinity 
DAT inhibition constants of N-substituted 2β-carbomethoxy-3β-(4’-methyl-
phenyl)-nortropanes varied in the range of 2.9 to 321 nM (Tables 2 and 3), which 
is roughly two orders of magnitude. Sterically bulky cyclohexyl (4j) derivative 
was not tolerated by the binding site, but larger benzyl (4f) and cinnamyl (4i) 
groups were much more potent. These substituents have one and three carbon 
atoms connecting the phenyl and amine groups. This increases flexibility of the 
substituent and possibility for aromatic-aromatic interactions. 
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The possibility of kinetic differentiation between these two mechanisms is 
illustrated by simulation results. A more thorough analysis of kinetic models is 
described in paper III. 
35 
Table 2 DAT binding affinities (Ki) and equilibrium binding 
constants (KL) of N-substituted 2β-carbomethoxy-3β-(4’-
methylphenyl)nortropanes. Data from papers II and IV. 
 
 
Compound R Ki ± SEM, nM KL ± SEM, nM 
3 H  19  ± 3  26  ± 10 
4e CH2cC3H5  36  ± 4  30  ± 7 
4f CH Ph  33  ± 6  56  ± 23 
4g CH CH=CH2  65  ± 13  96  ± 44 
4h CH2CH=CHCH3  53  ± 6  53  ± 18 
4j cC6H5  321 ± 43  474  ± 160 
2α-PE2I CH2CH=CHI  (39  ± 8) · 103  (58  ± 23) · 103 
 
Homological series of N-alkyl nortropane derivatives (3, 2, 4a–4d) showed no 
clear dependence between number of carbon atoms and DAT potency, i.e. there 
seems to be no correlation between substituent size and protein affinity among 
linear alkyl chains. Within this series, increase of carbon chain length from 
methyl (2) to propyl (4b) leads to a decrease in potency of compounds, but 
further increase of length, up to n-pentyl (4d), increases DAT affinity. An 
arbitrary explanation could be the change in orientation of the ligand in the 
binding pocket or increase of hydrophobic interactions. 
N-allylic substituents reveal a clear correlation between DAT affinity and 
substituent size, in the order of potency: cinnamyl (4i) > iodoallyl (PE2I) > bro-
moallyl (6) > crotyl (4h) > allyl (4g). This tendency implies that a somewhat 
rigid three carbon structural fragment in the ligand structure is needed if large 
substituents are desired at N-position of nortropane core. In addition, it seems 
that the phenyl group and halogens of allyl derivatives contribute by gain of 
interactions with the binding site. 
The inhibition constant values of compounds 2 and 3, in addition to 
thoroughly characterized PE2I, have previously been reported, revealing 
variable results. In theory, the Ki values should be independent of experimental 
conditions. The DAT affinity (Ki) of 2 in the literature varies between 1.5 and 
32 nM, which agree with inhibition constant determined here (Table 3).149,150 
Similarly to compound 2, the potency of 3 is also overestimated in the 
literature149 with DAT affinity of 0.8 nM compared to 19 nM (Table 2). The inhi-
bition constant, determined in this work, of PE2I agrees with a previous report13 
but slightly differs from 17 nM reported before73. The fact that different 
inhibition constant values are published for the same compounds is a common 
problem in the literature, and hinders constructing large structure-activity 
relationships. 
2
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Table 3 DAT binding affinities (Ki), equilibrium binding constants 
(KL) and rate constants of isomerization of N-substituted  
2β-carbomethoxy-3β-(4’-methylphenyl)nortropanes. Data from 
papers II and IV. 
 
 
 
 
It is clear that the N-substituent alters the inhibition constant values of 
nortropane derivatives. Several substituted derivatives had increased potencies 
over the N-unsubstituted nortropane (2), revealing an enhancement of 
interactions between substituted ligand and the protein. 
 
 
Kinetic profiles of ligand-DAT interaction 
The dissimilarities of Ki and KL are evident among ligands capable of inducing 
the isomerization step (Table 3). Splitting overall affinity (Ki) into initial 
binding (KL) and isomerization (Kisom) constants can only be achieved by the 
analysis of their kinetic profiles. The on-rate constants of the isomerization 
process varied from 0.005 to 0.055 s–1 and revealed no correlation between 
ligand size and ki. The off-rate constants (k–i) are rather similar to one another, 
ranging from 0.0024 to 0.0048 s–1 (Table 3). 
The kinetic profiles, in this case the observed rate (kobs) of reporter ligand 
binding versus concentration of unlabeled ligand plots, between the ligands 
analyzed here are shown in Figures 6 and 7. It can be seen, that in many cases 
the presence of the non-radioactive ligand increased the observed rate, pointing 
to the fact that additional slow isomerization step follows the fast initial ligand 
binding step (Scheme 10). In the case of other ligands, decrease in the kobs 
values can be seen in the presence of unlabeled ligands, pointing to the fact that 
Compd R Ki ± SEM, 
nM 
ki, s−1 k−i, s−1 KL ± SEM, 
nM 
Kisom 
2 CH3 5.7 ± 0.7 0.055 ± 0.002 – 11 ± 2 1.08 
4a CH2CH3 14 ± 2 0.035 ± 0.020 – 21 ± 2 2.00 
4b (CH2)2CH3 32 ± 3 0.037 ± 0.002 – 65 ± 19 0.97 
4c (CH2)3CH3 20 ± 2 0.05 ± 0.02 – 47 ± 11 0.74 
4d (CH2)4CH3 9.6 ± 1.1 0.012 ± 0.001 0.0042 ± 0.0005 36 ± 9 0.36 
4i CH2CH=CHPh 2.9 ± 0.3 0.036 ± 0.006 0.0048 ± 0.0001 41 ± 9 0.08 
6 CH2CH=CHBr 6.8 ± 1.1 0.005 ± 0.001 0.0046 ± 0.0003 23 ± 9 0.42 
PE2I CH2CH=CHI 4.8 ± 1.0 0.020 ± 0.008 0.0024 ± 0.0003 37 ± 24 0.15 
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no isomerization of the complex was observed in their interaction with DAT 
(Scheme 9). 
Similarly to inhibition constant, the ability to form a slowly dissociating 
complex does not directly correlate with N-substituent size among the data 
discussed here. In case of smaller homological subsets, e.g. N-allyl or linear  
N-alkyl, there seems to be a relationship between ligand volume and the 
presence of isomerization step. For example, N-allyl- (4g) and N-crotyl- (4h) 
substituted ligands (Table 1) exhibit only fast kinetics, while larger iodo- 
(PE2I), bromo- (6) and phenylallyl (4i) derivatives show a slow step with 
increasing on-rate constant of the slow step (ki) with increasing size. Benzyl 
(4f), cyclohexyl (4j) and methyl cyclopropyl (4e) derivatives revealed only 
rapid kinetics (Table 2, Figures 6 and 7). 
In the homological N-alkyl series of 2β-carbomethoxy-3β-(4’-methyl-
phenyl)-nortropanes both fast and slow kinetics can be seen. Nortropane (3) 
displayed only rapid complex, while N-pentyl derivative (4d) showed a clear 
isomerization step. N-methyl (2), ethyl (4a), propyl (4b) and butyl (4c) sub-
stituted nortropanes revealed an isomerization step, which was interfered by 
high concentrations of the same ligand. This non-hyperbolic kinetics was 
observed among four ligands (2, 4a, 4b and 4c in Figure 6) studied here. A 
decrease in the observed rate constant at relatively high concentrations of the 
unlabeled ligand could be caused by phenomenon, that is analogues to substrate 
inhibition, common in enzyme kinetics151. These non-hyperbolic curves are the 
results of two to one stoichiometry between ligand and protein. If this is the 
case, DAT can accommodate a second ligand with affinities five to tenfold less 
potent than the primary binding site. 
The difference between overall affinity (Ki) and initial binding equilibrium 
(KL) is somewhat expressed by Kisom, i.e. equilibrium constant describing the 
extent of isomerization of the ligand-DAT complex. Ligands, showing only fast 
kinetics, have similar or indistinguishable Ki and KL values and, therefore, the 
isomerization phenomena is absent or insignificant. 
The ligands, binding only in rapid complexes, show a declining plateau at 
approximately 0.022 s–1 when extrapolating the hyperbola. This limit is set by 
the isomerization rate constants of the radioligand, [3H]PE2I. The upper plateau 
of ligands, exhibiting slow isomerization step (e.g. 4d, 4i and 6), is directly 
related to their on-rate constants. The plateau is higher with increasing on-rate 
constants of unlabeled ligands. 
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Figure 6. The effects of concentrations of compounds 2, 3 and 4a-4f on the observed 
rate constant. 
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Figure 7. The effects of concentrations of compounds 4g-4j, PE2I and 2α-PE2I on the 
observed rate constant. 
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The role of ligand size to binding mechanism 
Systematic structure-activity analysis was not an objective of this study, but still 
the data indicated some trends connected with ligand structure. The influence of 
molecule size, represented by molar refractivity (MR), to the dissociation 
constants was analyzed and the resulting trends are briefly summarized below. 
In order to analyze the effect of the size of compounds on ligand-protein 
interaction, MR is correlated with the equilibrium binding and isomerization 
constants. The negative logarithm of the first equilibrium binding constants 
(pKL) versus MR plot reveals a slight declining trend between them (Figure 8a), 
i.e. increase in N-substituent size results in a small decline of initial complex 
formation. This indicates that the first step of DAT interaction depends little on 
ligand size and larger ligands might have a slight steric hindrance upon initial 
binding. The same tendency seems to govern both ligand types with isomeri-
zation step and those without it. The first step of interaction is the molecular 
recognition of the compound by the protein. This tendency is not surprising 
since the diffusion of smaller molecules to the binding pocket is less restricted 
than that of a large molecule. 
In order to explain high DAT affinity for some large ligands, considering 
declining KL, an overall increase in affinity from isomerization component is 
needed. Ligands exhibiting isomerization step retain their potency by the 
increased contribution of the second binding equilibria, characterized by Kisom. It 
can be seen that the equilibrium is shifted towards slowly dissociating complex 
with increasing ligand size (Figure 8b), showing that the only option to retain 
DAT potency for a large ligand involves extending the isomerization step. 
Molar refractivity was chosen in this case to represent the size of the molecule, 
and therefore, assess the shifts of equilibrium constants with increasing size, 
resulting in the simplest of structure-activity and structure-kinetics relationships. 
This study could be extended by the addition of more complex models and 
further modification of ligand structure to yield additional kinetic and 
equilibrium constants followed by a more thorough analysis of structural 
characteristics leading to those properties. Since the factors governing off-rate 
kinetics of any ligand-protein system are only very vaguely understood, the 
structure-kinetics relationships could be an invaluable asset to screening of 
compounds with desirable kinetics. 
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Figure 8. The effect of ligand size on the subsequent binding constants; ligands exhibiting 
only rapid kinetics (blue), ligands capable of initiating isomerization step (red), ligands 
capable of forming an isomerization step and a second rapid complex at high con-
centrations (green). 
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CONCLUSIONS 
Cocaine analogues interact with DAT in two distinct mechanisms, which differ 
from one another by the presence or absence of a slow isomerization step. 
These interaction mechanisms can be differentiated by means of kinetic 
analysis, while common displacement studies do not allow this differentiation. 
Therefore, the results of this study provide unique opportunity to analyze the 
influence of ligand structure on the mechanism of their interaction with DAT, 
including their ability to induce a slow isomerization step. 
Among the inhibitors analyzed here, all ligands with DAT affinities in the 
order of 10 nM or below initiated a slow isomerization step. This means that the 
overall gain in DAT affinity is contributed by the slow isomerization step and 
allows to speculate that all tropane-based high affinity DAT inhibitors owe their 
binding effectiveness to the slow step. Other ligands, with DAT affinities 
characterized by higher Ki values, ranging up to 321 nM in this study, did not 
initiate the slow isomerization step. 
Contribution of the isomerization step increased with ligand size and the 
largest ligand displayed the highest potency. This means that the isomerization 
step is sensitive to ligand structure, similarly with ligand recognition in the fast 
binding step. Gaining knowledge about the slow isomerization step and how 
this step is influenced by structure may be useful for the design of drugs with 
increased binding effectiveness. This also means that all structure-activity 
relationships only based on Ki values, without any further verification of kinetic 
mechanism of binding process, may provide inadequate models. 
In some cases, the isomerization process was inhibited by the ligand excess 
that is analogous with substrate inhibition phenomenon in enzyme kinetics, 
pointing to the possibility of formation of additional complexes in DAT 
inhibition. 
The activation energy of thermal inactivation shows a positive linear 
correlation between protein molecular weight and activation energy. The 
thermal inactivation energy of membrane protein is lower than that of a soluble 
protein of similar size, therefore, the membrane is responsible for the lower 
activation energy. This is also a reminder that protein solubilization or proteins 
expressed in non-mammalian cells can alter the function and bioactivity. 
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SUMMARY 
A series of N-substituted 2β-carbomethoxy-3β-(4’-methylphenyl)nortropanes 
were synthesized and their interactions with rodent dopamine transporter were 
studied. In addition to conventional equilibrium displacement studies, kinetics 
of interaction of these ligands to DAT was assayed, which allowed to further 
specify the ligand-protein interaction mechanism. It was found that several 
congeners were able to induce an additional slow conformational transition of 
the ligand-protein complex that increases the apparent DAT affinity. Among 
these ligands were some which deviated from the simple competitive models by 
displaying non-hyperbolic kinetics. This phenomenon, occurring at high con-
centrations, is not yet fully understood and needs further analysis. 
The kinetic experiments were performed by monitoring the effect of 
unlabeled ligands to the binding kinetics of a single radiolabeled ligand 
[3H]PE2I to DAT. In order to fully comprehend this kinetic approach, a general 
reaction scheme was compiled, ordinary differential equation system was 
constructed and solved numerically to yield simulated binding curves. Results 
of these simulations were used to formulate kinetic tools for differentiation 
between distinct ligand interaction mechanisms and identifying compounds 
capable of forming slowly dissociating complexes. 
Characterization of fast and slow steps in the overall ligand binding process, 
and distinction between compounds, which are able and which are not able to 
induce the slow conformational transition of the transporter protein, opens an 
opportunity to analyze molecular recognition of these ligands by DAT. All 
ligands with apparent affinity around or below 10 nM were capable of inducing 
a slow conformational transition of protein-ligand complex, indicating the 
necessity of this property for efficient drugs. It can be proposed that all tropane-
based high affinity DAT ligands owe their binding effectiveness to the slow 
step, and therefore, by increasing the contribution of the isomerization step, 
even more potent inhibitors could be designed. Although the proof of principle 
was illustrated in the case of tropane derivatives binding to DAT, modulation of 
overall binding effectiveness by an additional slow step could be used for other 
ligand-protein systems. 
Only by modifying substituents at the nitrogen position of nortropane, the 
affinity of compounds changed from 3 to 321 nM. This variation was also 
sufficient to modify the ligand binding mechanism. N-Allyl derivatives showed 
a positive correlation between substituent size and DAT affinity, indicating the 
need of a moderately rigid chain of at least three carbons between the N atom of 
tropane bicycle and a bulky substituent. This allows retaining or even increasing 
transporters affinity for tropane-based ligands with increasing molecular weight. 
Thermal stability of mouse and rat dopamine transporters was determined by 
measuring the loss of activity at a range of temperatures. Arrhenius equation 
allowed calculation of activation energy and half-lives of thermal inactivation. 
The activation energy values were compared to other soluble and membrane 
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proteins which showed an increase in activation energy with increasing molecular 
weight. Membrane proteins were significantly more labile than soluble proteins 
of similar size. Results of this study conformed the understanding about the 
significant role of lipid environment on DAT stability, and perhaps also on its 
kinetic behavior in the ligand binding process. 
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SUMMARY IN ESTONIAN 
N-Asendatud nortropaani derivaatide kineetilised aspektid 
seondumisel dopamiini transportvalguga 
Käesoleva töö käigus sünteesiti seeria N-asendatud nortropaani derivaate ning 
määrati nende tasakaalulised ja kineetilised konstandid seondumisel dopamiini 
transportvalguga (DAT). See võimaldas täpsustada ligandide seondumise 
mehhanismi, mille tulemusena tuvastati mitmed ühendid, mis olid võimelised 
moodustama aeglaselt dissotsieeruva ligand-valk kompleksi ning seeläbi 
suurendasid valgu näivat afiinsust ligandi suhtes. Tasakaalu tingimustes tehtud 
katsetes neid mehhanismi eripärasid tuvastada ei ole võimalik. 
Kineetilistes mõõtmistes kasutati triitiumiga märgistatud reporterligandi 
[3H]PE2I (N-(3-iodoprop-2E-enüül)-2β-karbometoksü-3β-(4’-metüülfenüül)-
nortropaan) ning uuriti selle ligandi DAT-ile seostumise kineetikat mitte-
radioaktiivsete ainete juuresolekul. Tulemusena saadi reporterligandi valgule 
seondumise näivad kiiruskonstandid, mille väärtusi mõjutasid märgistamata 
ligandid. Saadud sõltuvused võimaldasid iseloomustada valguga seondumise 
mehhanismi. 
Eksperimentaalsete tulemuste interpreteerimise lihtsustamiseks koostati kahe 
ligandi samaaegset seondumist kirjeldav üldskeem, mille põhjal tuletati harilike 
diferentsiaalvõrrandite süsteem, mida omakorda lahendati numbriliselt. Tule-
musena saadi ligandi seondumist valgule kirjeldavad simulatsioonikõverad, 
millest koostati märgistamata ligandi kontsentratsiooni ja näilise kiiruskonstandi 
vahelised sõltuvused. Formuleeriti reeglid, mis võimaldavad eristada reakt-
sioonimehhanisme, mis erinevad ligand-valk kompleksi aeglase isomerisat-
siooni esinemise poolest peale kiire sidumise staadiumit. 
Mõned isomerisatsiooni initsieerivad ligandid näitasid mittehüperboolset 
kineetikat, mis tähendab et kõrgemate ligandi kontsentratsioonide juures tuvastati 
näilise kiiruskonstandi langust. See nähtus on sarnane ensüümkineetikast teada 
oleva substraatpidurdusega, ning viitab asjaolule, et need ligandid võivad 
toimida DAT-i alternatiivse sidumistsentriga. See avab uusi võimalusi selle 
sihtmärkvalguga toimivate ainete loomiseks. 
Ainuüksi nortropaani derivaatide N-asendaja varieerimine muutis DAT 
afiinsust 3–321 nM ning selles derivaatide reas muutus ka reaktsioonimehha-
nism. Kiirelt ja aeglaselt seostuvate mehhanismide eristamine võimaldab kirjel-
dada isomerisatsiooni osa nende toime efektiivsuses. Kõik käesolevas töös 
analüüsitud ligandid, mille inhibeerimiskonstant oli alla 10 nM, moodustasid 
aeglaselt dissotsieeruva kompleksi. See viitab isomerisatsiooni olulisusele kõrge 
bioaktiivsusega ühendites seas. Seondudes DATiga moodustavad tõenäoliselt 
kõik kõrge DAT afiinsusega inhibiitorid aeglase isomerisatsiooni staadiumi, 
mistõttu on lisastaadiumi efekti suurendamine üks võimalustest ligandide 
aktiivsuste tõstmiseks. Aeglane staadium, pärast esmast kiiret seondumist, 
esineb ka mitmete teiste ligand-valk süsteemide korral, mistõttu oleks ka siis 
võimalik rakendada kineetilisi uuringuid, et tuvastada isomerisatsiooni roll. 
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Biomembraani integreeritud DAT-i stabiilsuse uuringud temperatuuri suhtes 
võimaldasid arvutada valgu inaktivatsiooni aktivatsioonienergia. Saadud 
aktivatsioonienergia väärtusi võrreldi teiste kirjanduses olevate membraan-ja 
lahustuvate valkude väärtustega ning ilmnes positiivne korrelatsioon, mis 
tähendab, et valgu molekulmassi suurenedes suurenes ka inaktivatsiooni aktivat-
sioonienergia. Kusjuures membraanvalgud olid tunduvalt vähem stabiilsemad 
kui sarnaste suurustega lahustuvad valgud. See kinnitab membraani olulisust 
DAT stabiilsusele ning ka suure tõenäosusega valgu funktsioonile. 
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